Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Caplin Point Laboratories's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 16.13%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Caplin Point Laboratories's 3-Year ROIIC % or its related term are showing as below:
NSE:CAPLIPOINT's 3-Year ROIIC % is ranked better than 67.44% of 946
companies
in the Drug Manufacturers industry
Industry Median: 3.635
vs NSE:CAPLIPOINT: 16.13
Caplin Point Laboratories (NSE:CAPLIPOINT) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Caplin Point Laboratories 3-Year ROIIC % Related Terms
Caplin Point Laboratories 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:CAPLIPOINT vs ZTS, UTHR: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Caplin Point Laboratories's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caplin Point Laboratories 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Caplin Point Laboratories's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Caplin Point Laboratories's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Caplin Point Laboratories (NSE:CAPLIPOINT) has a 3-Year ROIIC % of 16.13 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Caplin Point Laboratories and its competitors. This is 29% below median its historical median of 22.59. Over the past decade, Caplin Point Laboratories' 3-Year ROIIC % has ranged from 16.13 to 179.05. According to the industry distribution chart, Caplin Point Laboratories ranks #308 out of 946 companies in the Drug Manufacturers industry, placing it in the top 32.6%.
Is Caplin Point Laboratories' 3-Year ROIIC % too high?
Caplin Point Laboratories' current 3-Year ROIIC % of 16.13 is 29% below median its 10-year median of 22.59. Over the past 10 years, this metric has ranged from a low of 16.13 to a high of 179.05. The Drug Manufacturers industry median 3-Year ROIIC % is 3.64. Caplin Point Laboratories' value of 16.13 is 343.7% above this industry median. Based on the distribution chart, Caplin Point Laboratories ranks #308 out of 946 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Caplin Point Laboratories has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caplin Point Laboratories' 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Caplin Point Laboratories ranks #308 out of 946 companies for 3-Year ROIIC %. This puts Caplin Point Laboratories in the upper half of its industry. The industry median 3-Year ROIIC % is 3.64. Caplin Point Laboratories' value of 16.13 is 343.7% above this benchmark. Historically, Caplin Point Laboratories' own 3-Year ROIIC % has ranged from 16.13 to 179.05 over the past decade. While the company's 10-year median is 22.59 vs. the industry median of 3.64, Caplin Point Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.64, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Caplin Point Laboratories's current 3-Year ROIIC % of 16.13 is 343.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Caplin Point Laboratories and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caplin Point Laboratories's current 3-Year ROIIC % is 16.13, which is 29% below median its own 10-year median of 22.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caplin Point Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Caplin Point Laboratories (NSE:CAPLIPOINT) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,088.62, compared to a current price of ₹2,671.50 — trading 27.9% above its estimated fair value. The current 3-Year ROIIC % is 16.13, which is 29% below median its 10-year median of 22.59 and 343.7% above the Drug Manufacturers industry median of 3.64. Caplin Point Laboratories' overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Caplin Point Laboratories (NSE:CAPLIPOINT), the current 3-Year ROIIC % is 16.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Caplin Point Laboratories (NSE:CAPLIPOINT) Overvalued in 2026?
Based on GuruFocus' analysis, Caplin Point Laboratories stock appears to be overvalued.
The current stock price of ₹2,671.50 is trading 27.9% above its estimated GF Value™ of ₹2,088.62.
GuruFocus considers Caplin Point Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:CAPLIPOINT:
3-Year ROIIC %: 16.13 (29% below median its 10-year median of 22.59)
GF Value™: ₹2,088.62 vs. price of ₹2,671.50 (27.9% above fair value)
Industry Position: 343.7% above the Drug Manufacturers median (#308 of 946)
No single metric tells the full story. See the NSE:CAPLIPOINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Caplin Point Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, injections (liquid and lyophilized, prefilled syringes), ophthalmic solutions, liquid orals, soft gel capsules, ointments, creams, gels, powders for injections, suppositories, ovules, pre-mix bag formulations, inhalers, sprays, and IV infusions. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops.
88GF Score
Get the complete analysis for NSE:CAPLIPOINT
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CAPLIPOINT has been successfully added to your 
